HARRISBURG — Attorney General Dave Sunday is urging Pennsylvanians who are taking GLP-1 drugs to be sure they are getting those drugs from licensed pharmacies — as supplies have not kept pace with an overwhelming consumer demand, prompting the emergence of a counterfeit market for the diabetes control and weight-loss drugs.

Sunday recently urged the Food and Drug Administration, in a multistate coalition letter, to crack down on the counterfeit drugs, often originating from foreign countries.

Now, as people and families look forward to holidays, beach vacations and time in the sun, he encouraged Pennsylvanians to prioritize their health over efforts to lose a few more pounds.

“These counterfeit products flooding the market can cause harm, and I strongly advise anyone shopping for GLP-1 drugs to use extreme caution,” Sunday said. “I continue to urge the FDA to use its investigative, inspection and enforcement powers to protect consumers.”

Common weight loss and diabetes management drugs, known as GLP-1 receptor agonists, have become very popular nationwide, sold as Mounjaro, Zepbound, Ozempic and Wegovy.

Inadequate supply has created opportunities for bad actors seeking to profit from shortages and high costs and demand.

Consumers are urged to report suspicious products to the FDA and the Pennsylvania Office of Attorney General.

More information on GLP-1s can be found online.